Anastrozole is an aromatase inhibitor — an approved oral medicine whose whole job is to block one enzyme. Unlike almost everything else on this site, it isn't a peptide and isn't injected; it's a tablet with a well-documented FDA label. It comes up in testosterone-therapy discussion for one specific reason: the enzyme it blocks is the one that turns testosterone into estrogen.
In plain terms: it turns down the body's testosterone-to-estrogen conversion.
What aromatase does
Aromatase is an enzyme — a biological tool — that converts androgens (male-type hormones like testosterone) into estrogens (estradiol)1. This conversion is normal and happens in everyone. Anastrozole is a non-steroidal aromatase inhibitor: it sits on that enzyme and stops the conversion, so less estrogen gets made.
By the numbers on the FDA label, a 1 mg daily dose of anastrozole reduced estradiol (the main estrogen) by about 70% within 24 hours and roughly 80% after two weeks1. Notably, it does this without affecting the body's cortisol or aldosterone production — it's targeted to the estrogen-making step.
What it's approved for (and what it isn't)
Here's the honesty that vendor pages skip. Anastrozole's FDA-approved use is hormone-receptor-positive breast cancer in postmenopausal women, where cutting estrogen slows estrogen-fueled tumors1. That's the indication its large trial base supports.
Its appearance in a TRT context — managing the estrogen that rises when someone takes testosterone — is a different, off-label setting. This page describes the mechanism that makes it relevant there; it does not recommend it, and whether it's appropriate for any individual is a clinical decision.
Pharmacology at a glance
| Property | Anastrozole (per FDA label) |
|---|---|
| Class | Non-steroidal aromatase inhibitor |
| Action | Blocks androgen-to-estrogen conversion |
| Estradiol reduction (1 mg/day) | ~70% at 24 h; ~80% at 14 days |
| Terminal half-life | ~50 hours |
| Time to steady state | ~7 days of once-daily dosing |
| Route | Oral tablet |
Route: oral, not injected
Because anastrozole is a tablet, there's no reconstitution and no syringe math — the practical peptide skills don't apply. What matters instead is its pharmacokinetics: that ~50-hour half-life (half-life page) is long enough that levels accumulate to a steady state over about a week1.
Research context
Anastrozole appears alongside testosterone because the two act on the same androgen-estrogen balance from opposite directions — testosterone raises the input, anastrozole limits the conversion. It's also discussed near HCG in the same TRT-adjacent territory.
Latest research
- Anastrozole's core evidence — the large breast-cancer trials such as the ATAC program — remains its established base; it's one of the best-characterized aromatase inhibitors1.
- Its use to manage estrogen during testosterone therapy continues to be studied, but that remains an off-label context rather than an approved indication.
- We update this section as new research reports.
The short version
Anastrozole is an approved oral aromatase inhibitor: it blocks the enzyme that converts testosterone into estrogen, cutting estradiol by 70–80% at a 1 mg daily dose, with a long ~50-hour half-life. Its approval is for breast cancer; its TRT-adjacent role is off-label and described here for mechanism only. Not medical advice or a suitability assessment.